产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# AF6056, RRID:AB_2834975.
展开/折叠
70 kDa lamin; Cardiomyopathy dilated 1A (autosomal dominant); CDCD1; CDDC; CMD1A; CMT2B1; EMD2; FPL; FPLD; FPLD2; HGPS; IDC; Lamin A; Lamin A/C; Lamin A/C like 1; Lamin; Lamin C; Lamin-A/C; LDP1; LFP; LGMD1B; Limb girdle muscular dystrophy 1B (autosomal dominant); LMN 1; LMN A; LMN C; LMN1; LMNA; LMNA_HUMAN; LMNC; LMNL1; Prelamin A/C; PRO1; Renal carcinoma antigen NY REN 32; Renal carcinoma antigen NY-REN-32; Renal carcinoma antigen NYREN32;
抗原和靶标
In the arteries, prelamin-A/C accumulation is not observed in young healthy vessels but is prevalent in medial vascular smooth muscle cells (VSMCs) from aged individuals and in atherosclerotic lesions, where it often colocalizes with senescent and degenerate VSMCs. Prelamin-A/C expression increases with age and disease. In normal aging, the accumulation of prelamin-A/C is caused in part by the down-regulation of ZMPSTE24/FACE1 in response to oxidative stress.
- P02545 LMNA_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
METPSQRRATRSGAQASSTPLSPTRITRLQEKEDLQELNDRLAVYIDRVRSLETENAGLRLRITESEEVVSREVSGIKAAYEAELGDARKTLDSVAKERARLQLELSKVREEFKELKARNTKKEGDLIAAQARLKDLEALLNSKEAALSTALSEKRTLEGELHDLRGQVAKLEAALGEAKKQLQDEMLRRVDAENRLQTMKEELDFQKNIYSEELRETKRRHETRLVEIDNGKQREFESRLADALQELRAQHEDQVEQYKKELEKTYSAKLDNARQSAERNSNLVGAAHEELQQSRIRIDSLSAQLSQLQKQLAAKEAKLRDLEDSLARERDTSRRLLAEKEREMAEMRARMQQQLDEYQELLDIKLALDMEIHAYRKLLEGEEERLRLSPSPTSQRSRGRASSHSSQTQGGGSVTKKRKLESTESRSSFSQHARTSGRVAVEEVDEEGKFVRLRNKSNEDQSMGNWQIKRQNGDDPLLTYRFPPKFTLKAGQVVTIWAAGAGATHSPPTDLVWKAQNTWGCGNSLRTALINSTGEEVAMRKLVRSVTVVEDDEDEDGDDLLHHHHGSHCSSSGDPAEYNLRSRTVLCGTCGQPADKASASGSGAQVGGPISSGSSASSVTVTRSYRSVGGSGGGSFGDNLVTRSYLLGNSSPRTQSPQNCSIM
种属预测
score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。
High(score>80) Medium(80>score>50) Low(score<50) No confidence
翻译修饰 - P02545 作为底物
Site | PTM Type | Enzyme | Source |
---|---|---|---|
M1 | Acetylation | Uniprot | |
T3 | Phosphorylation | Uniprot | |
S5 | Phosphorylation | Uniprot | |
T10 | Phosphorylation | Uniprot | |
S12 | Phosphorylation | Uniprot | |
S17 | Phosphorylation | Uniprot | |
S18 | Phosphorylation | Uniprot | |
T19 | Phosphorylation | P06493 (CDK1) | Uniprot |
S22 | Phosphorylation | P28482 (MAPK1) , P06493 (CDK1) | Uniprot |
T24 | Phosphorylation | Uniprot | |
T27 | Phosphorylation | Uniprot | |
K32 | Ubiquitination | Uniprot | |
R41 | Methylation | Uniprot | |
Y45 | Phosphorylation | Uniprot | |
R48 | Methylation | Uniprot | |
S51 | Phosphorylation | Uniprot | |
T64 | Phosphorylation | Uniprot | |
S66 | Phosphorylation | Uniprot | |
S71 | Phosphorylation | Uniprot | |
S75 | Phosphorylation | Uniprot | |
K78 | Ubiquitination | Uniprot | |
Y81 | Phosphorylation | Uniprot | |
K90 | Ubiquitination | Uniprot | |
S94 | Phosphorylation | Uniprot | |
K97 | Acetylation | Uniprot | |
K97 | Sumoylation | Uniprot | |
K97 | Ubiquitination | Uniprot | |
S107 | Phosphorylation | Uniprot | |
K108 | Acetylation | Uniprot | |
K108 | Ubiquitination | Uniprot | |
K114 | Acetylation | Uniprot | |
K114 | Ubiquitination | Uniprot | |
K117 | Ubiquitination | Uniprot | |
K123 | Ubiquitination | Uniprot | |
K135 | Acetylation | Uniprot | |
K135 | Ubiquitination | Uniprot | |
S143 | Phosphorylation | Uniprot | |
K144 | Acetylation | Uniprot | |
K144 | Ubiquitination | Uniprot | |
S149 | Phosphorylation | Uniprot | |
T150 | Phosphorylation | Uniprot | |
S153 | Phosphorylation | Uniprot | |
K155 | Acetylation | Uniprot | |
K155 | Ubiquitination | Uniprot | |
T157 | Phosphorylation | Uniprot | |
R166 | Methylation | Uniprot | |
K171 | Acetylation | Uniprot | |
K171 | Ubiquitination | Uniprot | |
K180 | Acetylation | Uniprot | |
K180 | Ubiquitination | Uniprot | |
K181 | Ubiquitination | Uniprot | |
R189 | Methylation | Uniprot | |
T199 | Phosphorylation | Uniprot | |
K201 | Acetylation | Uniprot | |
K201 | Sumoylation | Uniprot | |
K201 | Ubiquitination | Uniprot | |
K208 | Acetylation | Uniprot | |
K208 | Sumoylation | Uniprot | |
K208 | Ubiquitination | Uniprot | |
Y211 | Phosphorylation | Uniprot | |
S212 | Phosphorylation | Uniprot | |
T218 | Phosphorylation | Uniprot | |
K219 | Sumoylation | Uniprot | |
K219 | Ubiquitination | Uniprot | |
T224 | Phosphorylation | Uniprot | |
K233 | Acetylation | Uniprot | |
K233 | Sumoylation | Uniprot | |
K233 | Ubiquitination | Uniprot | |
K260 | Acetylation | Uniprot | |
K260 | Sumoylation | Uniprot | |
K260 | Ubiquitination | Uniprot | |
K261 | Acetylation | Uniprot | |
K261 | Ubiquitination | Uniprot | |
K265 | Acetylation | Uniprot | |
K265 | Sumoylation | Uniprot | |
K265 | Ubiquitination | Uniprot | |
K270 | Acetylation | Uniprot | |
K270 | Sumoylation | Uniprot | |
K270 | Ubiquitination | Uniprot | |
S277 | Phosphorylation | Uniprot | |
S282 | Phosphorylation | Uniprot | |
S295 | Phosphorylation | Uniprot | |
S301 | Phosphorylation | P31749 (AKT1) | Uniprot |
S303 | Phosphorylation | Uniprot | |
S307 | Phosphorylation | O14757 (CHEK1) | Uniprot |
K311 | Acetylation | Uniprot | |
K311 | Sumoylation | Uniprot | |
K311 | Ubiquitination | Uniprot | |
K316 | Ubiquitination | Uniprot | |
K319 | Ubiquitination | Uniprot | |
S326 | Phosphorylation | Uniprot | |
Y359 | Phosphorylation | Uniprot | |
Y376 | Phosphorylation | Uniprot | |
K378 | Acetylation | Uniprot | |
K378 | Sumoylation | Uniprot | |
K378 | Ubiquitination | Uniprot | |
R386 | Methylation | Uniprot | |
S390 | Phosphorylation | P06493 (CDK1) | Uniprot |
S392 | Phosphorylation | P06493 (CDK1) | Uniprot |
T394 | Phosphorylation | Uniprot | |
S395 | Phosphorylation | Uniprot | |
S398 | Phosphorylation | Uniprot | |
S403 | Phosphorylation | Uniprot | |
S404 | Phosphorylation | P31749 (AKT1) | Uniprot |
S406 | Phosphorylation | Uniprot | |
S407 | Phosphorylation | Uniprot | |
T409 | Phosphorylation | Uniprot | |
S414 | Phosphorylation | Uniprot | |
T416 | Phosphorylation | Uniprot | |
K417 | Acetylation | Uniprot | |
K417 | Sumoylation | Uniprot | |
K417 | Ubiquitination | Uniprot | |
K418 | Acetylation | Uniprot | |
K418 | Ubiquitination | Uniprot | |
K420 | Sumoylation | Uniprot | |
K420 | Ubiquitination | Uniprot | |
S423 | Phosphorylation | Uniprot | |
T424 | Phosphorylation | Uniprot | |
S426 | Phosphorylation | Uniprot | |
S429 | Phosphorylation | Uniprot | |
S431 | Phosphorylation | Uniprot | |
S437 | Phosphorylation | Uniprot | |
K450 | Acetylation | Uniprot | |
K450 | Sumoylation | Uniprot | |
K450 | Ubiquitination | Uniprot | |
K457 | Acetylation | Uniprot | |
K457 | Ubiquitination | Uniprot | |
S458 | Phosphorylation | Uniprot | |
S463 | Phosphorylation | Uniprot | |
K470 | Acetylation | Uniprot | |
K470 | Methylation | Uniprot | |
K470 | Ubiquitination | Uniprot | |
T480 | Phosphorylation | Uniprot | |
Y481 | Phosphorylation | Uniprot | |
K486 | Sumoylation | Uniprot | |
K486 | Ubiquitination | Uniprot | |
T488 | Phosphorylation | Uniprot | |
T505 | Phosphorylation | Uniprot | |
S507 | Phosphorylation | Uniprot | |
T510 | Phosphorylation | Uniprot | |
K515 | Acetylation | Uniprot | |
C522 | S-Nitrosylation | Uniprot | |
S525 | Phosphorylation | Uniprot | |
T528 | Phosphorylation | Uniprot | |
S533 | Phosphorylation | Uniprot | |
T534 | Phosphorylation | Uniprot | |
S546 | Phosphorylation | Uniprot | |
T548 | Phosphorylation | Uniprot | |
S568 | Phosphorylation | Uniprot | |
S583 | Phosphorylation | Uniprot | |
T585 | Phosphorylation | Uniprot | |
T590 | Phosphorylation | Uniprot | |
K597 | Acetylation | Uniprot | |
K597 | Sumoylation | Uniprot | |
K597 | Ubiquitination | Uniprot | |
S599 | Phosphorylation | Uniprot | |
S601 | Phosphorylation | Uniprot | |
S603 | Phosphorylation | Uniprot | |
S612 | O-Glycosylation | Uniprot | |
S612 | Phosphorylation | Uniprot | |
S613 | Phosphorylation | Uniprot | |
S615 | Phosphorylation | Uniprot | |
S616 | Phosphorylation | Uniprot | |
S618 | Phosphorylation | Uniprot | |
S619 | Phosphorylation | Uniprot | |
T621 | Phosphorylation | Uniprot | |
T623 | Phosphorylation | Uniprot | |
S625 | Phosphorylation | Uniprot | |
S628 | Phosphorylation | Uniprot | |
S632 | Phosphorylation | Uniprot | |
S636 | Phosphorylation | Uniprot | |
T643 | O-Glycosylation | Uniprot | |
T643 | Phosphorylation | Uniprot | |
R644 | Methylation | Uniprot | |
S651 | Phosphorylation | Uniprot | |
S652 | Phosphorylation | Uniprot | |
T655 | Phosphorylation | Uniprot | |
S657 | Phosphorylation | Uniprot |
研究背景
Lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin. Lamin A and C are present in equal amounts in the lamina of mammals. Plays an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics. Required for normal development of peripheral nervous system and skeletal muscle and for muscle satellite cell proliferation. Required for osteoblastogenesis and bone formation. Also prevents fat infiltration of muscle and bone marrow, helping to maintain the volume and strength of skeletal muscle and bone. Required for cardiac homeostasis.
Prelamin-A/C can accelerate smooth muscle cell senescence. It acts to disrupt mitosis and induce DNA damage in vascular smooth muscle cells (VSMCs), leading to mitotic failure, genomic instability, and premature senescence.
Increased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations.
Proteolytic cleavage of the C-terminal of 18 residues of prelamin-A/C results in the production of lamin-A/C. The prelamin-A/C maturation pathway includes farnesylation of CAAX motif, ZMPSTE24/FACE1 mediated cleavage of the last three amino acids, methylation of the C-terminal cysteine and endoproteolytic removal of the last 15 C-terminal amino acids. Proteolytic cleavage requires prior farnesylation and methylation, and absence of these blocks cleavage.
Sumoylation is necessary for the localization to the nuclear envelope.
Farnesylation of prelamin-A/C facilitates nuclear envelope targeting.
Nucleus. Nucleus envelope. Nucleus lamina. Nucleus>Nucleoplasm.
Note: Farnesylation of prelamin-A/C facilitates nuclear envelope targeting and subsequent cleavage by ZMPSTE24/FACE1 to remove the farnesyl group produces mature lamin-A/C, which can then be inserted into the nuclear lamina. EMD is required for proper localization of non-farnesylated prelamin-A/C.
Nucleus speckle.
In the arteries, prelamin-A/C accumulation is not observed in young healthy vessels but is prevalent in medial vascular smooth muscle cells (VSMCs) from aged individuals and in atherosclerotic lesions, where it often colocalizes with senescent and degenerate VSMCs. Prelamin-A/C expression increases with age and disease. In normal aging, the accumulation of prelamin-A/C is caused in part by the down-regulation of ZMPSTE24/FACE1 in response to oxidative stress.
Homodimer of lamin A and lamin C. Interacts with lamin-associated polypeptides IA, IB and TMPO-alpha, RB1 and with emerin. Interacts with SREBF1, SREBF2, SUN2 and TMEM43. Interacts with TMEM201 (By similarity). Proteolytically processed isoform A interacts with NARF. Interacts with SUN1. Prelamin-A/C interacts with EMD. Interacts with MLIP. Interacts with DMPK; may regulate nuclear envelope stability. Interacts with SUV39H1; the interaction increases stability of SUV39H1. Interacts with SYNE2. Interacts with ITSN1 isoform 2.
Belongs to the intermediate filament family.
研究领域
· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)
· Human Diseases > Cardiovascular diseases > Hypertrophic cardiomyopathy (HCM).
· Human Diseases > Cardiovascular diseases > Arrhythmogenic right ventricular cardiomyopathy (ARVC).
· Human Diseases > Cardiovascular diseases > Dilated cardiomyopathy (DCM).
文献引用
Application: WB Species: Human Sample: MDA-MB-231 cells
限制条款
产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.